Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Intravenous replacement of extracellular fluid losses,Maintenance of fluid and electrolyte balance,Correction of metabolic acidosis,Off-label: Resuscitation in hypovolemia, perioperative fluid management
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable; Plasma-Lyte 148 contains electrolytes and water that distribute according to body fluid compartments; infusion rate and renal function dictate elimination; clinical context: in normal renal function, excess fluids and electrolytes are cleared with a half-life of approximately 2-4 hours.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Acetate and gluconate are metabolized in the liver and kidneys to bicarbonate. Water and electrolytes are not metabolized but undergo renal excretion.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal: >90% of infused electrolytes and water are excreted unchanged in urine. Biliary/fecal excretion is negligible (<1%).
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Not applicable; individual electrolytes do not bind to plasma proteins (e.g., sodium, chloride, potassium, magnesium, acetate, gluconate have negligible protein binding).
Negligible for electrolytes and dextrose (<5%).
Not applicable as a single value; electrolytes distribute into total body water (approximately 0.6 L/kg in adults); clinical meaning: initial distribution reflects extracellular fluid expansion.
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100% (directly into systemic circulation).
Intravenous: 100%.
No specific dose adjustment; use with caution in renal impairment due to risk of electrolyte imbalances. Monitor serum electrolytes and renal function.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Intravenous infusion; dose based on weight and clinical status. Typical rate: 5-20 m L/kg/hour, adjust based on response.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Use with caution due to potential for fluid overload and electrolyte disturbances; monitor renal function and adjust infusion rate accordingly.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
None
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of fluid overload, especially in patients with heart failure or renal impairment,Electrolyte disturbances (hypernatremia, hyperkalemia, hypokalemia, hypercalcemia, hypermagnesemia) may occur,Monitor serum electrolytes, fluid balance, and renal function,Not recommended for use in patients with severe renal impairment or anuria,Use with caution in patients with metabolic alkalosis or conditions with predisposing factors for electrolyte imbalances
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hypersensitivity to any component,Severe renal impairment with oliguria or anuria,Hyperkalemia,Metabolic alkalosis,Clinically significant hypercalcemia,Patients with conditions where sodium retention is a concern (e.g., congestive heart failure, edema, cirrhosis)
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
None; PLASMA-LYTE 148 is administered intravenously and does not interact with food. However, patients with electrolyte imbalances may require dietary adjustments (e.g., low potassium or low sodium diet) as directed by their physician.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. No trimester-specific risks reported.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Plasma-Lyte 148 components are endogenous and normally present in breast milk. No specific M/P ratio available; expected to be safe during lactation with usual clinical monitoring.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Pregnancy may increase total body water and electrolyte requirements; dose adjustments are generally not required but individualize based on maternal status and volume deficits.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
PLASMA-LYTE 148 is a balanced crystalloid solution with physiologic concentrations of electrolytes and p H 7.4. It is preferred over normal saline in patients with hyperchloremic metabolic acidosis or renal impairment. Avoid in patients with severe hyperkalemia, hypercalcemia, or metabolic alkalosis. Do not administer simultaneously with blood products through the same IV line due to risk of hemolysis from calcium content.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution is given intravenously to replace fluids and electrolytes.,Report any signs of allergic reaction like rash, itching, or difficulty breathing immediately.,Tell your healthcare provider if you have kidney disease, heart failure, or are on a low-sodium diet.,Inform your doctor if you are pregnant, breastfeeding, or taking any medications.,The infusion site should be monitored for redness, swelling, or pain.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 is an isotonic crystalloid solution that provides electrolyte replacement and volume expansion. It mimics plasma electrolyte composition, with acetate and gluconate as bicarbonate precursors that are metabolized to bicarbonate in the liver and kidneys, helping to maintain acid-base balance.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is: Intravenous infusion; dose determined by electrolyte and fluid requirements. Typical adult rate: 25-100 m L/hour.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER is classified as Category C. No fetal risks have been associated with Plasma-Lyte 148 in Water. It is an isotonic crystalloid solution containing electrolytes and water, lacking known teratogenic properties. N. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.